Spain's rare diseases strategy moves up a gear
This article was originally published in Clinica
Spain has officially inaugurated the national reference centre (CRE) for rare diseases, which will take forward an R&D and care strategy that the health ministry is describing as "pioneering" at European level. The centre, built and equipped at a cost of €13.6m ($20m), is located in Burgos and will also serve as the hub for activities being developed regionally.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.